Pyrimidine: A Privileged Scaffold for the Development of Anticancer Agents as Protein Kinase Inhibitors (Recent Update)
- PMID: 39773052
- DOI: 10.2174/0113816128346900241111115125
Pyrimidine: A Privileged Scaffold for the Development of Anticancer Agents as Protein Kinase Inhibitors (Recent Update)
Abstract
The pyrimidine nucleus is a fundamental component of human DNA and RNA, as well as the backbone of many therapeutic agents. Its significance in medicinal chemistry is well-established, with pyrimidine derivatives receiving considerable attention due to their potent anticancer properties across various cancer cell lines. Numerous derivatives have been synthesized, drawing structural inspiration from known anticancer agents like dihydropyrimidine compounds, which include the active cores of drugs such as 5-fluorouracil and monastrol, both of which have demonstrated strong anticancer efficacy. Additionally, various pyrimidine derivatives have been developed through different synthetic pathways, exhibiting promising anticancer potential. In response to the growing need for effective cancer treatments, recent efforts have focused on synthesizing and exploring novel pyrimidine derivatives with improved efficacy and specificity. This review aims to highlight the versatility of pyrimidine-based compounds in cancer therapy, emphasizing not only their potency and binding affinity but also their optimal interaction with diverse biological targets. The goal is to facilitate the design of new pyrimidine derivatives with enhanced anticancer potential, providing effective solutions for the treatment of various cancer types.
Keywords: Pyrimidine nucleus; anticancer; cancer therapy; dihydropyrimidine compounds; immunopathogenesis.; protein kinase inhibitors.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Amide Functionalized Novel Pyrrolo-pyrimidine Derivative as Anticancer Agents: Synthesis, Characterization and Molecular Docking Studies.Anticancer Agents Med Chem. 2025;25(6):420-432. doi: 10.2174/0118715206333935241004070350. Anticancer Agents Med Chem. 2025. PMID: 39506418
-
Synthetic Strategies of Pyrimidine-Based Scaffolds as Aurora Kinase and Polo-like Kinase Inhibitors.Molecules. 2021 Aug 26;26(17):5170. doi: 10.3390/molecules26175170. Molecules. 2021. PMID: 34500603 Free PMC article. Review.
-
Pyrimidine scaffold dual-target kinase inhibitors for cancer diseases: A review on design strategies, synthetic approaches, and structure-activity relationship (2018‒2023).Arch Pharm (Weinheim). 2025 Jan;358(1):e2400163. doi: 10.1002/ardp.202400163. Arch Pharm (Weinheim). 2025. PMID: 39828961 Review.
-
Discovery of thieno[2,3-d]pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents.Bioorg Chem. 2021 Jul;112:104947. doi: 10.1016/j.bioorg.2021.104947. Epub 2021 Apr 27. Bioorg Chem. 2021. PMID: 33964580
-
New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.Bioorg Chem. 2021 Oct;115:105208. doi: 10.1016/j.bioorg.2021.105208. Epub 2021 Jul 26. Bioorg Chem. 2021. PMID: 34365057
Cited by
-
Novel furo[2,3-d]pyrimidine derivatives as PI3K/AKT dual inhibitors: design, synthesis, biological evaluation, and molecular dynamics simulation.RSC Med Chem. 2025 Jun 17. doi: 10.1039/d5md00139k. Online ahead of print. RSC Med Chem. 2025. PMID: 40535840 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical